Weixiang Zhong1, Mingwu Chen, Lei Xian, Manhong Li. 1. Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China.
Abstract
BACKGROUND AND OBJECTIVE: Recent studies indicated that non-small cell lung cancer (NSCLC) patients with mutant K-ras were resistant to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). The aim of this study is to explore the relationship between the mutation of K-ras gene and NSCLC in Guangxi by detecting the point mutations in codon 12, 13 and 61 of K-ras gene in NSCLC. METHODS: The point mutations in codon 12, 13 and 61 of K-ras gene were detected by single-strand conformation polymorphism (SSCP) analysis of polymerase chain reaction (PCR) products and DNA sequencing analysis in 105 cases of NSCLC tissues and 30 cases of adjacent normal tissues. RESULTS: No point mutation in codon 12, 13 and 61 of K-ras gene was found in 105 cases of NSCLC tissues and 30 cases of adjacent normal tissues. In this study, the mutation frequency of K-ras gene in NSCLC was 0 (0/105). CONCLUSION: The high proportion of K-ras gene in wild-type indicates that patients with NSCLC in Guangxi could take more benefits from the therapy with EGFR-TKIs.
BACKGROUND AND OBJECTIVE: Recent studies indicated that non-small cell lung cancer (NSCLC) patients with mutant K-ras were resistant to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). The aim of this study is to explore the relationship between the mutation of K-ras gene and NSCLC in Guangxi by detecting the point mutations in codon 12, 13 and 61 of K-ras gene in NSCLC. METHODS: The point mutations in codon 12, 13 and 61 of K-ras gene were detected by single-strand conformation polymorphism (SSCP) analysis of polymerase chain reaction (PCR) products and DNA sequencing analysis in 105 cases of NSCLC tissues and 30 cases of adjacent normal tissues. RESULTS: No point mutation in codon 12, 13 and 61 of K-ras gene was found in 105 cases of NSCLC tissues and 30 cases of adjacent normal tissues. In this study, the mutation frequency of K-ras gene in NSCLC was 0 (0/105). CONCLUSION: The high proportion of K-ras gene in wild-type indicates that patients with NSCLC in Guangxi could take more benefits from the therapy with EGFR-TKIs.
K-ras-exon 2 PCR产物的SSCP图像(3 cm:9 cm)。1-12:已变性的PCR产物;1-7:NSCLC癌组织;8-12:癌旁正常肺组织;M:50 bp DNA marker;13:未变性的NSCLC癌组织PCR产物,作为实验对照组。
the SSCP image of PCR products for K-ras-exon 2 (3 cm:9 cm). 1-12: denatured products of PCR; 1-7: NSCLC tissues; 8-12: adjacent normal tissues; M: 50 bp DNA marker; 13: undenatured product of PCR in NSCLC tissue, as a control group.
3
K-ras-exon 3 PCR产物的SSCP图像(3 cm:9 cm)。1-11:已变性的PCR产物;1-8:NSCLC癌组织;9-11:癌旁正常肺组织;M:50 bp DNA marker。
the SSCP image of PCR products for K-ras-exon 3 (3 cm:9 cm). 1-11: denatured products of PCR; 1-8: NSCLC tissues; 9-11: adjacent normal tissues; M: 50 bp DNA marker.
K-ras-exon 2 PCR产物的SSCP图像(3 cm:9 cm)。1-12:已变性的PCR产物;1-7:NSCLC癌组织;8-12:癌旁正常肺组织;M:50 bp DNA marker;13:未变性的NSCLC癌组织PCR产物,作为实验对照组。the SSCP image of PCR products for K-ras-exon 2 (3 cm:9 cm). 1-12: denatured products of PCR; 1-7: NSCLC tissues; 8-12: adjacent normal tissues; M: 50 bp DNA marker; 13: undenatured product of PCR in NSCLC tissue, as a control group.K-ras-exon 3 PCR产物的SSCP图像(3 cm:9 cm)。1-11:已变性的PCR产物;1-8:NSCLC癌组织;9-11:癌旁正常肺组织;M:50 bp DNA marker。the SSCP image of PCR products for K-ras-exon 3 (3 cm:9 cm). 1-11: denatured products of PCR; 1-8: NSCLC tissues; 9-11: adjacent normal tissues; M: 50 bp DNA marker.
Authors: Karin E Finberg; Lecia V Sequist; Victoria A Joshi; Alona Muzikansky; Julie M Miller; Moonjoo Han; Javad Beheshti; Lucian R Chirieac; Eugene J Mark; A John Iafrate Journal: J Mol Diagn Date: 2007-07 Impact factor: 5.568
Authors: Erminia Massarelli; Marileila Varella-Garcia; Ximing Tang; Ana C Xavier; Natalie C Ozburn; Diane D Liu; Benjamin N Bekele; Roy S Herbst; Ignacio I Wistuba Journal: Clin Cancer Res Date: 2007-05-15 Impact factor: 12.531
Authors: S Forbes; J Clements; E Dawson; S Bamford; T Webb; A Dogan; A Flanagan; J Teague; R Wooster; P A Futreal; M R Stratton Journal: Br J Cancer Date: 2006-01-30 Impact factor: 7.640